BOLT - Company ID 0001641281
The table below shows Bolt Biotherapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $26.00K | $2.17M | $1.80M | $1.22M | $1.14M | $1.27M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $4.83M | $6.54M | $7.50M | $9.51M | $13.79M | $15.43M |
Bolt Biotherapeutics, Inc. reported annual revenue of $7.70M for fiscal year 2025. That is up 0.1% from $7.69M in fiscal 2024. Over the 6 fiscal years shown, annual revenue grew from $231.00K (FY 2020) to $7.70M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $2.80M |
| $3.34M |
| $3.52M |
| $3.83M |
| $3.80M |
| $4.87M |
| Operating income | -$7.60M | -$7.70M | -$9.21M | -$12.12M | -$16.44M | -$22.60M |
| Income tax | - | - | - | - | - | - |
| Net income | -$7.24M | -$7.14M | -$8.56M | -$11.04M | -$15.18M | -$21.20M |
| EPS (diluted) | -$4.31 | -$3.72 | -$4.46 | -$5.76 | -$7.93 | -$11.12 |